Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Whole blood RNA biomarkers for predicting survival in non-human primates following thoracic radiation

ABSTRACT: Whole blood RNA biomarkers for predicting survival in non-human primates following thoracic radiation

PROVIDER: PRJNA1103206 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR28773800_1.fastq.gz	Fastqsanger.gz
	SRR28773800_2.fastq.gz	Fastqsanger.gz
	SRR28773900_1.fastq.gz	Fastqsanger.gz
	SRR28773900_2.fastq.gz	Fastqsanger.gz
	SRR28774000_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 608

Similar Datasets

Whole blood RNA biomarkers for predicting survival in non-human primates following thoracic radiation

Project description:We conducted a comprehensive transcriptome analysis of whole blood from male and female nonhuman primates (rhesus macaque (Macaca mulatta)) that received upper thoracic radiation. A Varian CLINAC 21EX linear accelerator was used (6 MV Linear Accelerator (Linac)). Body Weight Range: 3.5 to 5 kg (at initial physical exam). Age Range: 3 to 5 years (at initial physical exam).

2024-09-30 | GSE264593 | GEO

Serum RNA biomarkers for predicting survival in non-human primates following thoracic radiation.

Project description:In a mass radiation exposure, the healthcare system may rely on differential expression of miRNA to determine exposure and effectively allocate resources. To this end, miRNome analysis was performed on non-human primate serum after whole thorax photon beam irradiation of 9.8 or 10.7 Gy with dose rate 600 cGy/min. Serum was collected up to 270 days after irradiation and sequenced to determine immediate and delayed effects on miRNA expression. Elastic net based GLM methods were used to develop models that predicted the dose vs. controls at 81% accuracy at Day 15. A three-group model at Day 9 achieved 71% accuracy in determining if an animal would die in less than 90 days, between 90 and 269 days, or survive the length of the study. At Day 21, we achieved 100% accuracy in determining whether an animal would later develop pleural effusion. These results demonstrate the potential ability of miRNAs to determine thorax partial-body irradiation dose and forecast survival or complications early following whole thorax irradiation in large animal models. Future experiments incorporating additional doses and independent animal cohorts are warranted to validate these results. Development of a serum miRNA assay will facilitate the administration of medical countermeasures to increase survival and limit normal tissue damage following a mass exposure.

| S-EPMC9296457 | biostudies-literature

Primates

Project description:Primates

| PRJNA551411 | ENA

Primates

Project description:Primates Raw sequence reads

| PRJNA320779 | ENA

Primates

Project description:Primates Raw sequence reads

| PRJNA342756 | ENA

Primates

Project description:Primates Raw sequence reads

| PRJNA984446 | ENA

Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin

Project description:RATIONALE: Studying samples of blood in the laboratory from patients receiving oxaliplatin for cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to neurotoxicity. PURPOSE: This phase II trial is studying biomarkers in predicting neurotoxicity in patients with colorectal cancer receiving oxaliplatin.

| 2071054 | ecrin-mdr-crc

A network-based framework to discover treatment-response-predicting biomarkers for complex diseases

Project description:Precision medicine's potential to transform complex autoimmune-disease treatment is often challenged by limited data availability and inadequate sample size when compared to the number of molecular features found in high-throughput multi-omics datasets. Addressing this issue, the novel framework PRoBeNet (Predictive Response Biomarkers using Network medicine) was developed. ProBeNet operates under the hypothesis that the therapeutic effect of a drug propagates through a protein–protein interaction network to reverse disease states. ProBeNet prioritizes biomarkers by considering (1) therapy-targeted proteins, (2) disease-specific molecular signatures, and (3) an underlying network of interactions among cellular components (the human interactome). With ProBeNet, biomarkers were discovered predicting patient responses to both an established autoimmune therapy (infliximab) and an investigational compound (a MAPK3/1 inhibitor). Predictive power of ProBeNet biomarkers was validated with retrospective gene-expression data from ulcerative-colitis and rheumatoid-arthritis patients and prospective data from ulcerative-colitis and Crohn’s disease patient-derived tissues. Machine-learning models using ProBeNet biomarkers significantly outperformed models using either all genes or randomly selected genes, especially when data were limited (fewer than 20 samples). These results illustrate the value of ProBeNet for reducing features and for constructing robust machine-learning models when limited data are available. ProBeNet may be used to develop companion and complementary diagnostic assays for complex autoimmune-disease therapies, which may help stratify suitable patient subgroups in clinical trials, approve new drugs, and improve patient outcomes.

2024-03-13 | GSE261205 | GEO

Identification of tumor-agnostic biomarkers for predicting prostate cancer progression and biochemical recurrence

Project description:Identification of tumor-agnostic biomarkers for predicting prostate cancer progression and biochemical recurrence

| PRJNA1023930 | ENA

A network-based framework to discover treatment-response-predicting biomarkers for complex diseases

Project description:A network-based framework to discover treatment-response-predicting biomarkers for complex diseases

| PRJNA1085755 | ENA